Cipla Ltd. Takes A Bite Out Of GlaxoSmithKline (GSK)'s Profits As Copy Of Top Asthma Drug Lauches In Germany, Sweden
9/2/2014 6:16:40 AM
Cipla Enters The Respiratory Market In Germany And Sweden With Affordable High Quality Alternatives
India, Mumbai,1st September 2014: Cipla, a global pharmaceutical company
announces today the
launch of Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden.
With this launch, Cipla
opens the door for new, highly efficient treatme
nts in the European healthcare market.
the affordability of Fixed Combinations in Europe
and help manage health costs
. “With Serroflo we offer in Germany and Sweden an alternative which is
tive and efficient and therefore brings many advantages into a market which suffers from limited
Mr. Frank Pieters, Head of Cipla Europe.
In Germany the new product is distributed under the name “Serroflo”,
in Sweden the
n is launched as “Salmeterol/Fluticasone Cipla”.
available in a pMDI with HFA propellant in two strengths:
1. 120 doses of 25/125 mcg salmeterol/fluticasone
2. 120 doses of 25/250 mcg salmeterol/fluticasone
Apart from Croatia where the combination is already available under the name Duohal, Germany and Sweden are amongst the first markets where Cipla is active and others will follow. “ Over the next 12 - 18
see a series of launches throughout
Europe as we know that there is a common need for
and thus sustainable therapy
and this is what Cipla stands
said Mr. Subhanu Saxena, Managing Director and Global CEO of Cipla Limited.
In Europe, about 30 million patients under 45 years suffer from asthma
causing a huge burden and
triggering significant disability and work loss. (ERS Lung white book 2013)
The introduction of
Salmeterol/Fluticasone in Germany and Sweden, is a key milestone in Cipla’s
ambition to improve
in asthma and to offer better healthcare solutions for patients
irrespective of what
disease they suffer from.
Cipla will also bring patient engagement programs aimed at enhancing disease
knowledge and improve adher
ence in order to achieve good disease control. Over 50 percent of patients
of asthma in Europe have suboptimal control and the introduction of Serroflo, Salmeterol/Fluticasone
Cipla will provide a new cost efficient option for many people with asthma.
Cipla is one of the worlds leading respiratory companies, with the largest range of drugs and devices
approved and sold in over a 100 countries.
In several markets, Cipla is prevalent in all therapy areas of
respiratory medicine, and was also the first to lau
nch several novel combinations, and drug/device.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet
the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most
respected pharmaceutical names in India as wel
l as across more than 170 countries. Our portfolio
includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover
in 2013/14 was 1.7 billion USD.
Whilst delivering a long
term sustainable business, Cipla recogn
ises its duty to provide affordable
medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role
played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti
retroviral (ARV) i
n Africa at less than one dollar a day and thereby treating many millions of patients
Cipla’s research and development focuses on developing innovative products and drug delivery systems
and has given India and the world many ‘firsts’ for i
nstance Triomune. In a tightly regulated
environment, the company’s manufacturing facilities have approvals from all the main regulators
including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one
universal standard both domest
ically and internationally.
Mob: +91 7506257377
Mob: +91 9833836185
Help employers find you! Check out all the jobs and post your resume.
comments powered by